{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:22:10Z","timestamp":1788186130179,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG"],"award-info":[{"award-number":["DFG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB295RETUNE"],"award-info":[{"award-number":["SFB295RETUNE"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Optic pathway gliomas are often asymptomatic tumors occurring in children with neurofibromatosis type 1 (NF1\u2009+\u2009OPG) or sporadically (spOPG). Treatment is usually prompted by visual loss and\/or tumor progression on MRI. The aim of this study was to investigate the relationship between visual acuity (VA), tumor growth, and contrast enhancement to provide more distinct indications for the administration of gadolinium-based contrast agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tumor load was retrospectively measured and enhancement semi-quantitatively scored on 298 MRIs of 35 patients (63% NF1\u2009+\u2009OPG). Spearman rank correlation between tumor load and enhancement was calculated and a linear mixed model used to examine the influence of tumor load and enhancement on corresponding VA tests (LogMAR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The optic nerve width in NF1\u2009+\u2009OPGs was strongly associated with VA (regression coefficient 0.75; confidence interval 0.61\u20140.88), but weakly with enhancement (0.06; \u22120.04\u20140.15). In spOPGs, tumor volume and optic nerve width were more relevant (0.31; \u22120.19\u20140.81 and 0.39; 0.05\u20140.73) than enhancement (0.09; \u22120.09\u20140.27).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tumor load measures may be more relevant for the surveillance of optic pathway gliomas than enhancement, given that VA is the relevant outcome parameter. Regular contrast administration should therefore be questioned in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-021-03941-1","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T13:02:53Z","timestamp":1641560573000},"page":"589-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma \u2013 a retrospective Magnetic Resonance Imaging study"],"prefix":"10.1007","volume":"156","author":[{"given":"Anna","family":"Kilian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Salchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Potratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich-Wilhelm","family":"Thomale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Hern\u00e1iz Driever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-9055","authenticated-orcid":false,"given":"Anna","family":"Tietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"issue":"2","key":"3941_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM et al (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A(2):327\u2013332","journal-title":"Am J Med Genet A"},{"issue":"3","key":"3941_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/WNO.0b013e31822aef82","volume":"31","author":"RA Avery","year":"2011","unstructured":"Avery RA, Fisher MJ, Liu GT (2011) Optic pathway gliomas. J Neuroophthalmol 31(3):269\u2013278","journal-title":"J Neuroophthalmol"},{"issue":"2","key":"3941_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-010-0159-z","volume":"100","author":"P Hern\u00e1iz Driever","year":"2010","unstructured":"Hern\u00e1iz Driever P, von Hornstein S, Pietsch T, Kortmann R, Warmuth-Metz M, Emser A et al (2010) Natural history and management of low-grade glioma in NF-1 children. J Neurooncol 100(2):199\u2013207","journal-title":"J Neurooncol"},{"issue":"7","key":"3941_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/pbc.22198","volume":"53","author":"G Nicolin","year":"2009","unstructured":"Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U et al (2009) Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 53(7):1231\u20131237","journal-title":"Pediatr Blood Cancer"},{"key":"3941_CR5","doi-asserted-by":"publisher","unstructured":"Azizi AA, Walker DA, Liu J-F, Sehested A, Jaspan T, Pemp B, et al (2020) NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol [Internet]. [cited 2020 Dec 4]; Available from: https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/https:\/\/doi.org\/10.1093\/neuonc\/noaa153\/5867970","DOI":"10.1093\/neuonc\/noaa153\/5867970"},{"issue":"6","key":"3941_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/jon.12450","volume":"27","author":"N Jittapiromsak","year":"2017","unstructured":"Jittapiromsak N, Hou P, Liu H-L, Sun J, Slopis JM, Chi TL (2017) Prognostic role of conventional and dynamic contrast-enhanced MRI in optic pathway gliomas. J Neuroimaging 27(6):594\u2013601","journal-title":"J Neuroimaging"},{"issue":"10","key":"3941_CR7","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1007\/s00247-018-4154-4","volume":"48","author":"E Maloney","year":"2018","unstructured":"Maloney E, Stanescu AL, Perez FA, Iyer RS, Otto RK, Leary S et al (2018) Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary? Pediatr Radiol 48(10):1472\u20131484","journal-title":"Pediatr Radiol"},{"key":"3941_CR8","doi-asserted-by":"crossref","unstructured":"Malbari F, Chintagumpala MM, Wood AC, Levy AS, Su JM, Okcu MF, et al. Gadolinium is not necessary for surveillance MR imaging in children with chiasmatic-hypothalamic low-grade glioma. Pediatric Blood & Cancer. 2021;68(10):e29178.","DOI":"10.1002\/pbc.29178"},{"issue":"4","key":"3941_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.mric.2020.06.001","volume":"28","author":"JS McDonald","year":"2020","unstructured":"McDonald JS, McDonald RJ (2020) MR imaging safety considerations of gadolinium-based contrast agents: gadolinium retention and nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 28(4):497\u2013507","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"3941_CR10","doi-asserted-by":"publisher","unstructured":"Noda SM, Oztek MA, Stanescu AL, Maloney E, Shaw DWW, Iyer RS (2021) Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families. Pediatr Radiol [Internet]. [cited 2021 Dec 25]; Available from: https:\/\/doi.org\/10.1007\/s00247-021-04973-5","DOI":"10.1007\/s00247-021-04973-5"},{"issue":"86","key":"3941_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2018.07.010","volume":"1","author":"I Elbeshlawi","year":"2018","unstructured":"Elbeshlawi I, AbdelBaki MS (2018) Safety of gadolinium administration in children. Pediatr Neurol 1(86):27\u201332","journal-title":"Pediatr Neurol"},{"issue":"6","key":"3941_CR12","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro J, Witt O, Hern\u00e1iz Driever P, Bag AK, de Blank P, Kadom N et al (2020) Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21(6):e305\u2013e316","journal-title":"Lancet Oncol"},{"issue":"2","key":"3941_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3174\/ajnr.A5456","volume":"39","author":"CE Al-Haddad","year":"2018","unstructured":"Al-Haddad CE, Sebaaly MG, Tutunji RN, Mehanna CJ, Saaybi SR, Khamis AM et al (2018) Optic nerve measurement on MRI in the pediatric population: normative values and correlations. Am J Neuroradiol 39(2):369\u2013374","journal-title":"Am J Neuroradiol"},{"issue":"970","key":"3941_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1259\/bjr\/65246351","volume":"81","author":"T Taylor","year":"2008","unstructured":"Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T et al (2008) Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 81(970):761\u2013766","journal-title":"Br J Radiol"},{"key":"3941_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fpsyg.2017.00456","volume":"8","author":"JZ Bakdash","year":"2017","unstructured":"Bakdash JZ, Marusich LR (2017) Repeated measures correlation. Front Psychol 8:456","journal-title":"Front Psychol"},{"issue":"1","key":"3941_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1\u201348","journal-title":"J Stat Softw"},{"issue":"6","key":"3941_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/neuonc\/nos076","volume":"14","author":"MJ Fisher","year":"2012","unstructured":"Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ et al (2012) Visual outcomes in children with neurofibromatosis type 1\u2013associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14(6):790\u2013797","journal-title":"Neuro Oncol"},{"key":"3941_CR18","doi-asserted-by":"publisher","unstructured":"Maloney E, Perez FA, Iyer RS, Otto RK, Wright JN, Menashe SJ, et al (2021) Non-inferiority of a non-gadolinium-enhanced magnetic resonance imaging follow-up protocol for isolated optic pathway gliomas. Pediatr Radiol [Internet]. [cited 2021 Dec 25]; Available from: https:\/\/doi.org\/10.1007\/s00247-021-05226-1","DOI":"10.1007\/s00247-021-05226-1"},{"issue":"10","key":"3941_CR19","first-page":"1963","volume":"22","author":"L Kornreich","year":"2001","unstructured":"Kornreich L, Blaser S, Schwarz M, Shuper A, Vishne TH, Cohen IJ et al (2001) Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol 22(10):1963\u20131969","journal-title":"AJNR Am J Neuroradiol"},{"key":"3941_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","volume":"81","author":"AK Gnekow","year":"2017","unstructured":"Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J et al (2017) A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416\u00a0years) low grade glioma \u2013 a final report. Eur J Cancer 81:206\u2013225","journal-title":"Eur J Cancer"},{"issue":"21 Suppl 1","key":"3941_CR21","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG et al (2013) Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81(21 Suppl 1):S33-40","journal-title":"Neurology"},{"issue":"21 Suppl 1","key":"3941_CR22","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","volume":"81","author":"MJ Fisher","year":"2013","unstructured":"Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE et al (2013) Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 81(21 Suppl 1):S15-24","journal-title":"Neurology"},{"issue":"21","key":"3941_CR23","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ (2017) Response assessment in neuro-oncology clinical trials. J Clin Oncol 35(21):2439\u20132449","journal-title":"J Clin Oncol"},{"issue":"6","key":"3941_CR24","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","volume":"21","author":"C Erker","year":"2020","unstructured":"Erker C, Tamrazi B, Poussaint TY, Mueller S, Mata-Mbemba D, Franceschi E et al (2020) Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21(6):e317\u2013e329","journal-title":"Lancet Oncol"},{"key":"3941_CR25","first-page":"1","volume":"25","author":"T Campion","year":"2020","unstructured":"Campion T, Quirk B, Cooper J, Phipps K, Toescu S, Aquilina K et al (2020) Surveillance imaging of grade 1 astrocytomas in children: can duration and frequency of follow-up imaging and the use of contrast agents be reduced? Neuroradiology 25:1\u20136","journal-title":"Neuroradiology"},{"issue":"9","key":"3941_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00234-012-1010-3","volume":"54","author":"S Gaudino","year":"2012","unstructured":"Gaudino S, Quaglio FR, Schiarelli C, Martucci M, Tartaglione T, Gualano MR et al (2012) Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas. Neuroradiology 54(9):989\u2013995","journal-title":"Neuroradiology"},{"issue":"2","key":"3941_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/neuonc\/not154","volume":"16","author":"S Gururangan","year":"2014","unstructured":"Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S et al (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2014a Pediatric Brain Tumor Consortium study. Neuro Oncol 16(2):310\u2013317","journal-title":"Neuro Oncol"},{"issue":"8","key":"3941_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T et al (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19(8):1135\u20131144","journal-title":"Neuro Oncol"},{"key":"3941_CR29","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3389\/fneur.2018.01102","volume":"9","author":"A Zahavi","year":"2018","unstructured":"Zahavi A, Toledano H, Cohen R, Sella S, Luckman J, Michowiz S et al (2018) Use of optical coherence tomography to detect retinal nerve fiber loss in children with optic pathway glioma. Front Neurol 9:1102","journal-title":"Front Neurol"},{"issue":"2","key":"3941_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/IAE.0000000000002840","volume":"41","author":"A Marta","year":"2021","unstructured":"Marta A, Malheiro L, Coelho J, Po\u00e7as J, Gon\u00e7alves N, Sousa P et al (2021) Optical coherence tomography and optical coherence tomography angiography parameters in patients with phacomatosis. Retina 41(2):366\u2013372","journal-title":"Retina"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03941-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:29:30Z","timestamp":1645453770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03941-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03941-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional ethic committee (EA2\/026\/18) and conducted according to the good scientific practice guidelines of Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin. Consent was waived in this retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}